A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. At 72 weeks, ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

But with the FDA approval of Zepbound by drugmaker Eli Lilly, it looks like Wegovy is no longer the only obesity ... year and has been prescribed off-label for obesity. This is similar to the ...

Separate studies conducted by the respective manufacturers have showed that Zepbound, with its dual-acting effect, was linked to more weight loss than Wegovy, but until now, no studies have ...

Share on Pinterest Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more. Sascha Lotz/picture alliance via Getty Images The ...

Share on Pinterest To address the GLP-1 drug shortages, manufacturer Eli Lilly has ramped up production of Mounjaro and Zepbound. Scott Olson/Getty Images Zepbound ... are no longer in short ...

A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings ...

Wegovy is approved for people 12 and older. On Zepbound’s label, the FDA notes that the safety and effectiveness of Zepbound have not yet been established in teens or adolescents. McGowan ...

By Dani Blum The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes ...